Yasunobu Hashimoto
Kawaguchi, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 74 publications
Effectiveness and Safety of Enfortumab Vedotin Plus Pembrolizumab for Patients Aged 80 Years and Older With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study.
Journal: Anticancer research
Published: May 18, 2026
Real-World Outcomes of Adjuvant Pembrolizumab for Renal Cell Carcinoma: The Potential Role of PD-L1 as a Prognostic Biomarker.
Journal: Targeted oncology
Published: February 28, 2026
Comparison of clinical outcomes of cabozantinib plus nivolumab and lenvatinib plus pembrolizumab in patients with metastatic renal cell carcinoma.
Journal: International urology and nephrology
Published: February 28, 2026
Real-world outcomes of third-line systemic therapy after immune checkpoint inhibitor combinations and subsequent VEGFR-TKIs in advanced renal cell carcinoma.
Journal: Japanese journal of clinical oncology
Published: January 11, 2026
Midterm Outcomes of Combination Therapy With Immune Checkpoint Inhibitors and VEGFR-TKIs in Real-World Patients With Advanced Renal Cell Carcinoma.
Journal: International journal of urology : official journal of the Japanese Urological Association
Published: November 25, 2025
Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Interstitial Lung Disease, Induced by Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Carcinoma.
Journal: IJU case reports
Published: November 10, 2025
Clinical evaluation of medical and surgical complete responses in metastatic renal cell carcinoma treated with immune checkpoint inhibitor combination therapy.
Journal: International journal of clinical oncology
Published: November 04, 2025
Impact of Cytoreductive Nephrectomy on Immune Checkpoint Inhibitor Therapy: Treatment Outcomes of Immune Inhibitors Combination Therapies for Metastatic Renal Cell Carcinoma With Primary Kidney Tumors.
Journal: International journal of urology : official journal of the Japanese Urological Association
Published: July 22, 2025
Impact of starting dose of tyrosine kinase inhibitors on outcomes following combination therapy of immune checkpoint inhibitors with tyrosine kinase inhibitors for previously untreated advanced renal cell carcinoma.
Journal: Japanese journal of clinical oncology
Published: June 28, 2025
Impact of first-line dual immuno-oncology combination therapy versus immuno-oncology plus tyrosine kinase inhibitor on outcomes of second-line VEGFR-TKI in advanced RCC: a real-world multi-institutional analysis.
Journal: International urology and nephrology
Published: May 15, 2025
Outcomes of Enfortumab Vedotin Treatment in Patients Ineligible for the EV-301 Trial.
Journal: In vivo (Athens, Greece)
Published: May 02, 2025
Last Updated: 09/26/2026